Cargando…
Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay
BACKGROUND: Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) surrogate neutralization assays that obviate the need for viral culture offer substantial advantages regarding throughput and cost. The cPass SARS-CoV-2 Neutralization Antibody Detection Kit (GenScript) is the first suc...
Autores principales: | Papenburg, Jesse, Cheng, Matthew P, Corsini, Rachel, Caya, Chelsea, Mendoza, Emelissa, Manguiat, Kathy, Lindsay, L Robbin, Wood, Heidi, Drebot, Michael A, Dibernardo, Antonia, Zaharatos, Gerasimos, Bazin, Reneé, Gasser, Romain, Benlarbi, Mehdi, Gendron-Lepage, Gabrielle, Beaudoin-Bussières, Guillaume, Prévost, Jérémie, Finzi, Andrés, Ndao, Momar, Yansouni, Cedric P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135688/ https://www.ncbi.nlm.nih.gov/pubmed/34136587 http://dx.doi.org/10.1093/ofid/ofab220 |
Ejemplares similares
-
Specificity of SARS-CoV-2 Antibody Detection Assays against S and N Proteins among Pre-COVID-19 Sera from Patients with Protozoan and Helminth Parasitic Infections
por: Yansouni, Cedric P., et al.
Publicado: (2022) -
Laboratory Features of Trichinellosis and Eosinophilia Threshold for Testing, Nunavik, Quebec, Canada, 2009–2019
por: Harrison, Luke B., et al.
Publicado: (2022) -
Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS‐CoV‐2
por: Mendoza, Emelissa J., et al.
Publicado: (2020) -
Elicitation of Cluster A and Co-Receptor Binding Site Antibodies Are Required to Eliminate HIV-1 Infected Cells
por: Beaudoin-Bussières, Guillaume, et al.
Publicado: (2020) -
A Recent SARS-CoV-2 Infection Enhances Antibody-Dependent Cellular Cytotoxicity against Several Omicron Subvariants following a Fourth mRNA Vaccine Dose
por: Beaudoin-Bussières, Guillaume, et al.
Publicado: (2023)